ATLANTA, GA – – (Globe Newswire – July 27, 2023) – – Holzer & Holzer, LLC is investigating whether Kodiak Sciences Inc. (“Kodiak” or the “Company”) (NASDAQ: KOD) complied with federal securities laws.  On July 24, 2023, Kodiak released top line results from several Phase 3 studies, noting the “GLEAM and GLIMMER studies did not meet their primary efficacy endpoints” and announcing that the Company decided to discontinue further development of its product, tarcocimab. Following this news, the price of the Company’s stock dropped.

If you purchased Kodiak stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/kodiak/ to discuss your legal rights.